Nucleophosmin mutations in tumor and blood.docVIP

 PAGE \* MERGEFORMAT 33 Nucleophosmin mutations in tumor and blood Abstract Nucleophosmin (NPM) is a class of shuttling between nucleolus, nuclear transfer and cytoplasmic proteins. Recently in normal karyotype acute myeloid leukemia, myelodysplastic syndrome, and a few were found to have NPM gene mutations and protein in the cytoplasm translocation, mutation of the NPM may be through down-start p53 tumor suppressor Arf-induced cell cycle arrest activity and the and promote cell malignant proliferation. Clinical research suggests that, NPM mutations in acute myeloid leukemia patients prognosis, and can be used as indicators for monitoring of minimal residual leukemia. These findings suggest that NPM mutations may occur in myeloid leukemia has an important role. In this paper, NPM mutations in the blood of the research progress of tumors are reviewed. Keywords: nucleolar phosphoprotein hematologic malignancies Arf; P53 Nucleophosmin Mutations in Hematological Malignancies - Review Abstract Nucleophosmin (NPM) is a protein that shuttles between the nucleus, nucleoplasm and cytoplasm. NPM gene mutations and aberrant cytoplasmic NPM localization have been recently described in acute myelogenous leukemia (AML) with normal karyotype and in a few myelodysplastic syndromes. Expression of NPM mutant reduces the ability of Arf to initiate a p53 response and to induce cell cycle arrest. Clinical research has revealed that NPM mutations are relative to prognosis and can be used to monitor and quantify minimal residual disease (MRD) in AML patients with normal karyotype, therefore, these findings indicate that nucleophosmin mutations might contribute to illustration of myeloid leukemogenesis. In this paper, the research progress of nucleophosmin mutations in haematological malignancies was reviewed. Keywords: Nucleophosmin; haematological malignancies; Arf; P53 Nucleophosmin (nucleophosmin, NPM, B23, NO38, or NPM1) are located in n